Evens Skin Tone Helps fade sunspots & hyperpigmentation
The approval, announced on 23 July 2024, has made semaglutide the first weight loss drug to be prescribed to prevent cardiovascular events such as cardiovascular death, non-fatal heart attack and non-fatal stroke in people with established cardiovascular disease and a BMI higher or equal to 27kg/m 2
Independently tested for purity
The study explored differences between access in Medicare-aged patients (65-69 years of age) and patients nearing Medicare age (60-64 years of age)
Festuccia, Pierre-Gilles Blanchard, Kerstin Bellmann, Yves Deshaies, Andr Marette
Semaglutide injection improves body mass index (BMI) and overall body weight by regulating blood sugar and encouraging weight reduction